Aadi Bioscience (AADI)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	30.54 mm	30.54 mm	30.54 mm	30.54 mm	30.54 mm	30.54 mm
Cash burn (monthly)	3.53 mm	3.19 mm	4.47 mm	5.52 mm	5.23 mm	4.51 mm
Cash used (since last report)	15.09 mm	13.62 mm	19.09 mm	23.57 mm	22.33 mm	19.27 mm
Cash remaining	15.44 mm	16.92 mm	11.44 mm	6.97 mm	8.21 mm	11.27 mm
Runway (months of cash)	4.4	5.3	2.6	1.3	1.6	2.5

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

AADI institutional ownership history Ownership history

30.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	28	67	-58.2%
Opened positions	5	21	-76.2%
Closed positions	44	14	+214.3%
Increased positions	6	14	-57.1%
Reduced positions	9	22	-59.1%

13F shares	Current	Prev Q	Change
Total value	9.00 bn	16.64 bn	-45.9%
Total shares	7.63 mm	12.88 mm	-40.7%
Total puts	0.00	2.50 k	EXIT
Total calls	0.00	9.40 k	EXIT
Total put/call ratio	–	0.3	–

Largest owners	Shares	Value	Change
BML Capital Management	2.00 mm	$4.12 bn	NEW
EcoR1 Capital	1.85 mm	$3.33 mm	NEW
Biotechnology Value Fund L P	899.39 k	$21.72 mm	0.0%
Vanguard	765.99 k	$1.58 bn	0.0%
Vivo Panda	509.57 k	$0.00	0.0%
Renaissance Technologies	461.82 k	$951.35 mm	+5.1%
Acuitas Investments	438.76 k	$903.85 mm	+24.5%
BlackRock	242.89 k	$500.35 mm	NEW
Geode Capital Management	208.75 k	$430.13 mm	+1.1%
NTRS Northern Trust	68.47 k	$141.06 mm	-56.8%

Largest transactions	Shares	Bought/sold	Change
Avoro Capital Advisors	0.00	-2.85 mm	EXIT
BML Capital Management	2.00 mm	+2.00 mm	NEW
Acuta Capital Partners	0.00	-1.85 mm	EXIT
EcoR1 Capital	1.85 mm	+1.85 mm	NEW
Satter Management	659.00	-1.63 mm	-100.0%
Vivo Capital	0.00	-509.57 k	EXIT
Citadel Advisors	0.00	-493.14 k	EXIT
Soleus Capital Management	0.00	-333.23 k	EXIT
BLK BlackRock	0.00	-320.25 k	EXIT
BlackRock	242.89 k	+242.89 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

AADI insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
19 Dec 24	Baiteng Zhao	Stock Option Common Stock	Grant	Acquire A	No	No	2.32	61,192	141.97 k	61,192
3 Oct 24	David James Lennon	Common Stock	Sell	Dispose S	No	No	1.94	9,689	18.80 k	22,869
2 Oct 24	David James Lennon	Common Stock	Option exercise	Acquire M	No	No	0	32,558	0.00	32,558
2 Oct 24	David James Lennon	RSU Common Stock	Option exercise	Dispose M	No	No	0	32,558	0.00	0
3 Sep 24	Neil Desai	Common Stock	Sell	Dispose S	Yes	Yes	1.7079	40,000	68.32 k	1,171,543
5 Aug 24	Neil Desai	Common Stock	Sell	Dispose S	Yes	Yes	1.3437	5,652	7.59 k	1,211,543
2 Aug 24	Neil Desai	Common Stock	Sell	Dispose S	Yes	Yes	1.4105	18,933	26.70 k	1,217,195
1 Aug 24	Neil Desai	Common Stock	Sell	Dispose S	Yes	Yes	1.4956	15,415	23.05 k	1,236,128

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?

20 Dec 24

Aadi Bioscience secures ADC portfolio license, involving $44 million upfront and $805 million in milestones plus royalties.

Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

20 Dec 24

Reported Earlier, Aadi Bioscience Secures $100M PIPE Financing, Sells FYARRO For $100M, And Licenses Three Novel ADC Assets

20 Dec 24

Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DACAadi Enters Agreement to Sell FYARRO® and Associated Infrastructure to KAKEN

Press releases

From Benzinga Pro

Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025

5 Feb 25

Proxy Statement Includes Proposals on Previously Announced Sale of FYARRO and Associated Infrastructure to Kaken for $100M, and $100M PIPE Financing to Support In-Licensing of ADC Portfolio Aadi's Board Recommends

Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing

19 Dec 24

Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO® and Associated Infrastructure to